Preparation of Immunotoxin Herceptin-Botulinum and Killing Effects on Two Breast Cancer Cell Lines

Background: Worldwide, breast cancer is the most common cancer diagnosed among women and a leading cause of cancer deaths. The age of onset in Iran has become reduced by a decade for unknown reasons. Herceptin, a humanized monoclonal antibody, is a target therapy for breast cancer cells with over ex...

Full description

Saved in:
Bibliographic Details
Published inAsian Pacific journal of cancer prevention : APJCP Vol. 16; no. 14; pp. 5977 - 5981
Main Authors Hajighasemlou, Saieh, Alebouyeh, Mahmoud, Rastegar, Hossein, Manzari, Mojgan Taghizadeh, Mirmoghtadaei, Milad, Moayedi, Behjat, Ahmadzadeh, Maryam, Parvizpour, Farzad, Johari, Behrooz, Naeini, Maria Moslemi, Farajollahi, Mohammad M
Format Journal Article
LanguageKorean
Published 2015
Subjects
botulinum toxin
SK-BR-3
BT-474
Breast cancer
HER2
herceptin
Online AccessGet full text

Cover

More Information
Summary:Background: Worldwide, breast cancer is the most common cancer diagnosed among women and a leading cause of cancer deaths. The age of onset in Iran has become reduced by a decade for unknown reasons. Herceptin, a humanized monoclonal antibody, is a target therapy for breast cancer cells with over expression of HER2-neu receptors, but it is an expensive drug with only 20% beneficial rate of survival. This study introduces a novel approach to enhance the efficacy of this drug through immunoconjugation of the antibody to botulinum toxin. Decreasing the cost and adverse effects of the antibody were secondary goals of this study. Materials and Methods: Botulinum toxin was conjugated with Herceptin using heterobifunctional cross linkers, succinimidyl acetylthiopropionate (SATP) and sulfo-succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) according to the supplier's guidelines and tested on two breast cancer cell lines: SK-BR-3 and BT-474. Toxin and Herceptin were also used separately as controls. The cytotoxicity assay was also performed using the new bioconjugate on cultured cells with Alamar blue and a fluorescence plate reader. Results: Herceptin-Toxin bioconjugation significantly improved Herceptin efficacy on both breast cancer cell lines when compared to the control group. Conclusions: Toxin-Herceptin bioconjugation can be a potential candidate with increased efficiency for treating breast cancer patients with over expression of the HER2 receptor.
Bibliography:KISTI1.1003/JNL.JAKO201528551642330
ISSN:1513-7368
2476-762X